Children with eosinophilic esophagitis (EoE) who receive early treatment with dupilumab may face a lower risk of developing asthma, according to data presented at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix.
The findings suggest a potential shift in managing atopic disease trajectories.
- Early dupilumab therapy is associated with a 7.9 percentage point reduction in incident asthma at 3.5 years compared to untreated children.
- The study observed these outcomes even in children who had discontinued the medication for at least one year.
- While the findings are promising, the retrospective nature of the analysis means it does not establish a direct cause-and-effect relationship.
Researchers analyzed 698 propensity-matched pairs of children to determine the association between early biologic intervention and the development of asthma. In the group treated with dupilumab, the incidence of asthma reached 8.1% at the 3.5-year mark. Conversely, children who did not receive the treatment saw an incidence rate of 16.0%.
The study, which utilized electronic health record data, matched participants based on age, sex, race, and history of atopic dermatitis. The mean age at the index event was 3.2 years, with approximately 74% of the cohort being male. “Early targeted biologic therapy may reduce incident asthma in children with EoE and may modify the trajectory of atopic disease,” K.J. Steinberger said.
| Metric | Dupilumab Group (N=698) | Untreated Group (N=698) |
|---|---|---|
| Mean Age at Index | 3.2 years | 3.2 years |
| Atopic Dermatitis History | 46.0% | 46.0% |
| Incident Asthma (3.5 years) | 8.1% | 16.0% |
Dupilumab is approved for the treatment of EoE in patients as young as 1 year old. Its indication for asthma, however, is restricted to patients 6 years and older. Because this study was retrospective, several variables—including specific dosing, total duration of therapy, and baseline EoE severity—remain unmeasured. These gaps leave the possibility of residual confounding, where other underlying health factors might have influenced which children were selected for treatment.
Future prospective, randomized controlled trials are required to confirm whether this biologic intervention truly prevents the onset of asthma or simply masks early symptoms. Current clinical practice must account for the fact that these findings represent an association observed in existing health records rather than a confirmed preventative strategy.
Dupilumab is not appropriate for all patients. Contraindications include a known hypersensitivity to the drug or any of its components. Patients should be monitored for signs of allergic reactions, including anaphylaxis or serum sickness.
Parents should consult a pediatric gastroenterologist or allergist if a child with EoE exhibits new respiratory symptoms such as persistent wheezing, nighttime coughing, or shortness of breath, as these may indicate an emerging asthma diagnosis regardless of current biologic therapy.
The long-term impact of early biologic use on the pediatric immune system remains an area of active investigation. Practitioners are encouraged to review the full clinical profile of the patient, including family history of atopic disease, before considering off-label or extended-use applications of biologic therapies.
- Steinberger KJ. Early dupilumab treatment for pediatric eosinophilic esophagitis is associated with reduced incident asthma. Presented at: American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.
